Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 6:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 3,286 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Pancreas Disease Clear all
Active, not recruiting No phase listed Observational

Methodist Acute Pancreatitis Protocol

NCT04214756
View directory record Official record
Conditions
Acute Pancreatitis (AP)
Interventions
Acute Pancreatitis
Procedure
Lead sponsor
Methodist Health System
Other
Eligibility
18 Years and older
Enrollment
500 participants
Timeline
2014 – 2026
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Jul 23, 2026, 6:21 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

NCT02711137
View directory record Official record
Conditions
Solid Tumors
Interventions
INCB057643, Gemcitabine, Paclitaxel, Rucaparib, Abiraterone, Ruxolitinib, Azacitidine
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
16
States / cities
Birmingham, Alabama • La Jolla, California • Denver, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Jul 23, 2026, 6:21 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan in Metastatic Pancreatic Cancer

NCT03535727
View directory record Official record
Conditions
Adenocarcinoma, Pancreatic Neoplasms, Neoplasm, Glandular, Neoplasms, Neoplasms Pancreatic, Digestive System Neoplasm, Endocrine Gland Neoplasms, Digestive System Disease, Pancreatic Diseases, Endocrine System Diseases
Interventions
Nab-paclitaxel, Gemcitabine, Capecitabine, Cisplatin, Irinotecan
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 76 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 30, 2024 · Synced Jul 23, 2026, 6:21 AM EDT
Completed Not applicable Interventional Results available

Early Intervention in Cystic Fibrosis Exacerbation

NCT01104402
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Home lung function and symptom monitoring
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
14 Years and older
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
3
States / cities
Baltimore, Maryland • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 22, 2017 · Synced Jul 23, 2026, 6:21 AM EDT
Completed Phase 1 Interventional

Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer

NCT04703920
View directory record Official record
Conditions
Metastatic Breast Cancer, Metastatic Castration-resistant Prostate Cancer, Metastatic Ovarian Carcinoma, Metastic or Unresectable Pancreatic Adenocarcinoma
Interventions
Talazoparib, Belinostat
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 22, 2025 · Synced Jul 23, 2026, 6:21 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Single Center Study of Islet Transplantation in Non-uremic Diabetic Patients

NCT01897688
View directory record Official record
Conditions
Type 1 Diabetes, Severe Hypoglycemic Unawareness
Interventions
Islet Cell Transplant
Biological
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Jul 23, 2026, 6:21 AM EDT
Withdrawn No phase listed Observational

Liver, Pancreas and Thyroid Function in Burn Patients

NCT03598283
View directory record Official record
Conditions
Burns, Liver Fibroses, Pancreas Disease, Thyroid Diseases
Interventions
Ultrasound/transient elastography
Device
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
6 Months and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 17, 2023 · Synced Jul 23, 2026, 6:21 AM EDT
Recruiting No phase listed Observational

Registry of Patients Undergoing Endoscopic Management of Pancreatic Fluid Collections

NCT06179459
View directory record Official record
Conditions
Acute Pancreatitis, Pancreatic Pseudocyst, Pancreatic Necrosis
Interventions
Endoscopic management of pancreatic fluid collections
Procedure
Lead sponsor
Orlando Health, Inc.
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Jul 23, 2026, 6:21 AM EDT
Completed Phase 3 Interventional

Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer

NCT01360853
View directory record Official record
Conditions
Metastatic Pancreatic Adenocarcinoma
Interventions
ON 01910.Na, Gemcitabine
Drug
Lead sponsor
Traws Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
30
States / cities
La Jolla, California • Palm Springs, California • Salinas, California + 27 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2016 · Synced Jul 23, 2026, 6:21 AM EDT
Completed Phase 3 Interventional Results available

Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine For Advanced Pancreatic Cancer.

NCT00471146
View directory record Official record
Conditions
Carcinoma, Pancreatic Ductal
Interventions
AG-013736, Gemcitabine, placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
630 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
77
States / cities
Antioch, California • Corona, California • Glendora, California + 57 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2012 · Synced Jul 23, 2026, 6:21 AM EDT
Recruiting Not applicable Interventional

Resection/Synchronous Pulmonary or Hepatic Oligometastatic Pancreatic Ductal Adenocarcinoma

NCT07340151
View directory record Official record
Conditions
Adenocarcinoma of the Pancreas
Interventions
Surgical resection
Procedure
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Jul 23, 2026, 6:21 AM EDT
Completed No phase listed Observational

Comparison of CLE in Vivo Diagnosis and ex Vivo Examination Against Surgical Histopathology of CPL

NCT02516488
View directory record Official record
Conditions
Cystic Pancreatic Disorders
Interventions
Not listed
Lead sponsor
Somashekar Krishna
Other
Eligibility
18 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 16, 2019 · Synced Jul 23, 2026, 6:21 AM EDT
Completed Phase 2 Interventional

A Study of Volociximab in Combination With Gemcitabine in Metastatic Pancreatic Cancer

NCT00401570
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Volociximab, Gemcitabine
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 29, 2013 · Synced Jul 23, 2026, 6:21 AM EDT
Completed Phase 1 Interventional

Can Aprotinin Reduce Pancreatitis After Scoliosis Surgery

NCT00357851
View directory record Official record
Conditions
Pancreatitis
Interventions
Aprotinin
Drug
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
Up to 18 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Wilmington, Delaware
Source: ClinicalTrials.gov public record
Updated Oct 13, 2010 · Synced Jul 23, 2026, 6:21 AM EDT
Terminated Not applicable Interventional

Gemcitabine Compared With Pancreatic Enzyme Therapy Plus Specialized Diet (Gonzalez Regimen) in Treating Patients Who Have Stage II, Stage III, or Stage IV Pancreatic Cancer

NCT00003851
View directory record Official record
Conditions
Malnutrition, Pancreatic Cancer
Interventions
proteolytic enzymes, gemcitabine hydrochloride, Gonzalez regimen
Biological · Drug · Procedure
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 14, 2013 · Synced Jul 23, 2026, 6:21 AM EDT
Completed Not applicable Interventional Results available

Feasibility Study of Closed Loop Control in Type 1 Diabetes Using Heart Rate Monitoring as an Exercise Marker

NCT01582139
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Heart rate informed SSM+HMM
Device
Lead sponsor
University of Virginia
Other
Eligibility
21 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 14, 2014 · Synced Jul 23, 2026, 6:21 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Cancer in Inherited Bone Marrow Failure Syndromes

NCT00027274
View directory record Official record
Conditions
Diamond Blackfan Anemia, Dyskeratosis Congenita, Fanconi Anemia, Shwachman Diamond Syndrome, Inherited Bone Marrow Failure Syndrome, Aplastic Anemia
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Day to 100 Years
Enrollment
4,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2001
U.S. locations
2
States / cities
Bethesda, Maryland • Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Jul 23, 2026, 6:21 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Integrin Alpha-v-Beta and [18F]-R01-MG-F2 PET/CT in Measuring Response in Patients With Pancreatic Cancer and Healthy Volunteers

NCT02683824
View directory record Official record
Conditions
Healthy Subject, Pancreatic Carcinoma
Interventions
Computed Tomography, Laboratory Biomarker Analysis, PET/MRI scan, [18F]FP-R01-MG-F2
Diagnostic Test · Other · Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Sep 20, 2023 · Synced Jul 23, 2026, 6:21 AM EDT
Terminated Not applicable Interventional

Diagnostic Endoscopic Exploration for Pancreatic Head Mass

NCT00816179
View directory record Official record
Conditions
Pancreatic Head Mass
Interventions
Transgastric diagnostic endoscopic peritoneoscopy
Procedure
Lead sponsor
Jeffrey Hazey
Other
Eligibility
18 Years to 80 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 2, 2014 · Synced Jul 23, 2026, 6:21 AM EDT
Completed Phase 3 Interventional Results available

Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have a Non-G551D CF Transmembrane Conductance Regulator (CFTR) Gating Mutation

NCT01614470
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Ivacaftor, Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
6 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
8
States / cities
Tampa, Florida • Atlanta, Georgia • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2014 · Synced Jul 23, 2026, 6:21 AM EDT
Completed Phase 2 Interventional Results available

A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors

NCT04704154
View directory record Official record
Conditions
Solid Tumors
Interventions
Regorafenib, (Stivarga, BAY73-4506), Nivolumab (Opdivo)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
6
States / cities
Duarte, California • Aurora, Colorado • Tampa, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2025 · Synced Jul 23, 2026, 6:21 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of VX 445/TEZ/IVA in Cystic Fibrosis Subjects 6 Through 11 Years of Age

NCT03691779
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
ELX/TEZ/IVA, IVA
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
6 Years to 11 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
13
States / cities
Orange, California • Aurora, Colorado • Chicago, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2021 · Synced Jul 23, 2026, 6:21 AM EDT
Completed Not applicable Interventional Results available

Closed Loop Control in Adolescents Using Heart Rate as Exercise Indicator

NCT01945060
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
heart rate Control to Range System (hrCTR) using DiAs Platform, DiAs Control-to-Range System not informed for heart rate
Device · Other
Lead sponsor
Marc Breton
Other
Eligibility
12 Years to 17 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
2
States / cities
Charlottesville, Virginia • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 20, 2023 · Synced Jul 23, 2026, 6:21 AM EDT
Completed Not applicable Interventional Results available

Stereotactic Radiation to Decrease Pancreatic Secretions

NCT01656486
View directory record Official record
Conditions
Pancreatic Fistulae
Interventions
Stereotactic Radiation
Radiation
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 70 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 9, 2022 · Synced Jul 23, 2026, 6:21 AM EDT